| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Alectinib |
| Brand | Alecensa® |
| Indication | For the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) whose disease has progressed following treatment with crizotinib. |
| Assessment Process | |
| Rapid review commissioned | 03/01/2017 |
| Rapid review completed | 27/02/2017 |
| Rapid review outcome | Full pharmacoeconomic evaluation recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations October 2017.
